安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric . . .
A phase Ib II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer Cancer Commun 43 , 150–153 (2023) Article Google Scholar
- Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy . . .
Background: Fruquintinib (F), a highly selective and potent oral inhibitor of VEGFRs 1, 2, and 3, significantly improved the OS in metastatic colorectal cancer (Li J, et al, JAMA 2018; Dasari A, et al, LANCET 2023) FRUTIGA was a randomized, double-blind, placebo (PBO)-controlled, phase 3 study evaluating the efficacy and safety of F plus paclitaxel (PTX) vs PTX alone in patients (pts) with
- Fruquintinib Bests Chemo in Advanced Gastric Cancer, but Questions Arise
In the newly reported FRUTIGA study, 699 patients were randomly assigned to receive fruquintinib plus paclitaxel or paclitaxel with a placebo Although ramucirumab is now a staple of care in advanced gastric cancer, Dr Xu noted that when the trial started in 2017, the monoclonal antibody had limited availability in China, so it was not included in the trial protocol
- Fruquintinib Plus Chemotherapy and PD-1 Inhibition Is Safe and Active . . .
Key Takeaways Fruquintinib combined with PD-1 inhibitors and chemotherapy showed promising efficacy in HER2-negative advanced gastric GEJ adenocarcinoma, with a median PFS of 9 43 months
- Fruquintinib Paclitaxel Improves PFS, ORR in Gastric . . . - Cancer Network
“Fruquintinib plus paclitaxel could be a promising second-line treatment option for patients with advanced gastric GEJ adenocarcinoma who have [progressed on] fluoropyrimidine- or platinum-containing chemotherapy,” presenting author Rui-Hua Xu, MD, PhD, a professor of medical oncology at Sun Yat-sen University Cancer Center, State Key
- A phase Ib II study of fruquintinib in combination with paclitaxel as . . .
Fruquintinib is a highly selective small‐molecule inhibitor of VEGFR‐1, VEGFR‐2, and VEGFR‐3 tyrosine and has shown an encouraging anti‐tumor activity against multiple cancer types Notably, in the recent phase III FRESCO trial ( NCT02314819 ), single‐agent fruquintinib significantly prolonged overall survival (OS) and PFS in
- Adding Fruquintinib to Paclitaxel Improves PFS in Gastric, GEJ Cancer
Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or gastroesophageal junction cancer, according to researchers Fruquintinib plus paclitaxel could be
- Phase 3 FRUTIGA Study of Fruquintinib Elicits Positive Results in . . .
The phase 3 FRUTIGA study (NCT03223376) of fruquintinib (Elunate) in combination with paclitaxel in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma met one of its primary end points of statistically significant improvement of progression-free survival (PFS), according to HUTCHMED Limited 1 While the trial was positive with mostly clinically meaningful data
|
|
|